From the Journals

MIS-C cardiac evaluation requires more than EF


 

FROM THE JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Comprehensive LV evaluation needed

The findings reinforce that myocardial involvement is more frequent and sometimes more severe in MIS-C than previously thought, said Kevin G. Friedman, MD, a pediatrician at Harvard Medical School, Boston, and an attending physician in the department of cardiology at Boston Children’s Hospital. “We are underestimating it by using just traditional measures like ejection fraction. It requires a comprehensive evaluation of left ventricular function; it really affects all aspects of the ventricle, both the systolic function and the diastolic function.”

Dr. Kevin G. Friedman, a pediatrician at Harvard Medical School, Boston, and an attending physician in the department of cardiology at Boston Children's Hospital

Dr. Kevin G. Friedman

This study supports that MIS-C patients should have a more detailed analysis than EF on echocardiography, including strain imaging. “Probably these patients should all be followed at centers where they can evaluate a more detailed analysis of the LV and RV function,” he said. Patients with ongoing CA enlargement and LV dysfunction should have follow-up cardiac care indefinitely. Patients who have no cardiac symptoms during the acute phase probably don’t need long-term follow-up.

“We’re just trying to learn more about this disease, and it’s certainly concerning that so many kids are having cardiac involvement,” Dr. Friedman said. “Fortunately they’re getting better; we’re just trying to find out what this means for the long term.”

Dr. Matsubara and Dr. Friedman have no relevant financial disclosures.

SOURCE: Matsubara D et al. J Am Coll Cardiol. 2020 Sep 2. doi: 10.1016/j.jacc.2020.08.056.

Pages

Recommended Reading

Dapagliflozin benefits low-EF heart failure regardless of diuretic dose: DAPA-HF
MDedge Endocrinology
SGLT2 inhibitors, developed for T2D, now ‘belong to cardiologists and nephrologists’
MDedge Endocrinology
SGLT2 inhibitors have a breakout year
MDedge Endocrinology
Empagliflozin failed to improve exercise capacity in heart failure
MDedge Endocrinology
Heart damage even after COVID-19 ‘recovery’ evokes specter of later heart failure
MDedge Endocrinology
Non-COVID-19 clinical trials grind to a halt during pandemic
MDedge Endocrinology
First evidence of SARS-CoV-2 in heart cells
MDedge Endocrinology
FDA pulls amputation boxed warning off canagliflozin label
MDedge Endocrinology
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit solidifies class effects
MDedge Endocrinology
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
MDedge Endocrinology